AbbVie Earnings: Maintaining Our Fair Value Estimate Following a Steady Second Quarter
Morningstar Equity Research said AbbVie (ABBV) reported 10.2% top-line growth and 22.9% adjusted diluted EPS growth in Q2. Management raised 2026 revenue guidance by $300 million to $67.6 billion but trimmed adjusted diluted EPS guidance to $13.87-$14.07 due to the pending Apogee acquisition. Morningstar maintained a $200 fair value estimate.
How this was made
The 30-second read
Why it matters
Traders can use the guidance split (revenue up, adjusted EPS range slightly down) to update near-term expectations and model sensitivity to acquisition timing and integration costs.
Market read
This is a guidance update anchored to Q2 performance and acquisition-related EPS uncertainty, with specific pipeline and competitive watchpoints that can drive incremental positioning.
What to watch
The note emphasizes pipeline inclusion decisions and early-stage data watchpoints; if upcoming competitor data (Icotyde in psoriatic arthritis) disappoints, the competitive overhang could ease faster than expected.
Background
Morningstar frames AbbVie’s Q2 as steady execution with immunology strength, while highlighting that EPS guidance is constrained by the pending Apogee acquisition.
Ticker impact
AbbVie reported 10.2% revenue growth and raised 2026 revenue guidance by $300 million to $67.6 billion, while adjusting EPS guidance lower due to the pending Apogee acquisition.
Likely supports a steady-to-slightly positive bias, but EPS guidance narrowing/lowering can cap upside until acquisition terms and integration details clarify.
The article provides specific guidance changes (revenue up, adjusted EPS range slightly down) and ties the EPS adjustment directly to the pending Apogee acquisition, which is a near-term valuation driver.
Market effects
Reinforces continued strength in immunology (Skyrizi, Rinvoq) despite competitive pressure in IL-23 and oral IL-23, which can influence sentiment across large pharma immunology peers.
Limited direct regional read-through; primarily US large-cap pharma sentiment.
Competition and pipeline watchpoints (including Icotyde and ADC/bi-specific programs) are globally relevant for pharma oncology and immunology positioning.
Counterpoint
The revenue guidance raise may be offset by acquisition-related EPS uncertainty, so the market could re-rate the stock on integration risk rather than organic growth strength.
Key entities
- companyAbbVie
Reported Q2 growth, raised 2026 revenue guidance, and slightly lowered adjusted diluted EPS guidance range due to the pending Apogee acquisition.
- companyApogee
Pending acquisition referenced as the reason for the adjusted diluted EPS guidance range being slightly lowered.
- productSkyrizi
Reported sales growth of 24% as it gains share in dermatology indications.
- productRinvoq
Reported growth of 25%, supported by alopecia and vitiligo approvals and pending US approval.
- productIcotyde
Oral IL-23 drug mentioned as a competitive factor, with psoriatic arthritis data expected later this year.
